BYD Company Limited
002594
Orient Group Incorporation
600811
Chifeng Jilong Gold Mining
600988
4
Kweichow Moutai
600519
5
Gree Electric Appliances,Inc.of Zhuhai
000651
CN Stock MarketDetailed Quotes
002019 Yifan Pharmaceutical
- 11.00
- -0.01-0.09%
Market Closed Mar 4 15:00 CST
13.38BMarket Cap-40.29P/E (TTM)
11.06High10.90Low64.18KlotVolume10.95Open11.01Pre Close70.47MTurnover0.76%Turnover RatioLossP/E (Static)1.22BShares14.3052wk High1.57P/B9.26BFloat Cap9.8452wk Low12.11Limit Up841.47MShs Float34.21Historical High9.91Limit Down1.45%Amplitude-0.15Historical Low0.10Dividend TTM10.98Avg Price33.94KlotAsk0.91%Div YieldTTM100Lot Size29.34KlotBid
Yifan Pharmaceutical News
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Yifan Pharmaceutical (002019.SZ): In the future, the company will continue to strive to explore key areas such as target discovery, compound screening, molecular design, pharmaceutical research, and clinical studies.
On February 24, Glonghui reported that Yifan Pharmaceutical (002019.SZ) has stated on the investor interaction platform that the company has begun to design some auxiliary tools and predictive functions in the field of macromolecule drug research and development. In the field of chemical drug research and development, applications have also been made in patent analysis, process route design, impurity evaluation, and pharmacological toxicology analysis. In the future, the company will continue to strive to attempt key areas such as target discovery, compound screening, molecular design, pharmaceutical research, and clinical research, dedicated to reducing research and development costs and improving research and development efficiency through cutting-edge technology.
Yifan Pharmaceutical (002019.SZ): The data organization and analysis for the Phase IB clinical trial of Duanjin detoxification capsules is expected to be completed by mid-year.
Gelonghui reported on February 17 that Yifan Pharmaceutical (002019.SZ) stated on the investor interaction platform that the clinical trial phase IB for the product Duanjin Detoxification Capsules is expected to complete data sorting and analysis by mid-year.
Yifan Pharmaceutical (002019.SZ): Currently, Yili Shu is exported to the USA using the EXW method, meaning that the buyer bears the customs duties.
On February 14, Gelonghui reported that Yifan Pharmaceutical (002019.SZ) stated on the investor interaction platform that currently, Yilishu is exported to the USA using EXW (Ex Works) delivery terms, meaning the buyer is responsible for the customs duties. If the final customs duties have a significant impact, negotiations will be conducted with the partners to find a joint solution.
Yifan Pharmaceutical (002019.SZ): subsidiary recognized as a high-tech enterprise.
On February 13, Gelonghui reported that Yifan Pharmaceutical (002019.SZ) announced that its holding subsidiary, Peking Jisheng Kantai International Pharmaceutical Technology Co., Ltd. (referred to as "Peking Jisheng Kantai"), and its wholly-owned subsidiary, Yifan Pharmaceutical Research Institute (Peking) Co., Ltd. (referred to as "Yifan Research Institute"), received the "High-tech Enterprise Certificate" issued on February 12, 2025, by the Peking Municipal Science and Technology Commission, the Peking Municipal Finance Bureau, and the National Taxation Administration Peking Tax Bureau.
Yifan Pharmaceutical Unit Wins Procurement Bid for Traditional Chinese Medicine
Express News | Yifan Pharmaceutical: Ginkgo Leaf Pills selected for the national Chinese Patent Medicine procurement alliance centralized procurement.
Yifan Pharmaceutical: 2024 Annual Performance Forecast
Yifan Pharmaceutical (002019.SZ): Projected profit for the year 2024 is 0.376 billion yuan to -0.52 billion yuan, turning losses into profits year-on-year.
On January 23, Gelonghui reported that Yifan Pharmaceutical (002019.SZ) announced its performance forecast for 2024, expecting a net income attributable to shareholders of the listed company to be between 0.376 billion yuan and 0.52 billion yuan, marking a turnaround from loss to profit year-on-year; the net income after excluding non-recurring gains and losses is estimated to be between 0.238 billion yuan and 0.356 billion yuan; and the EPS is projected to be between 0.31 yuan/share and 0.43 yuan/share. In 2024, the company anticipates an increase in sales volume of both new and existing proprietary pharmaceutical products (including imports), resulting in higher gross profit. The company's asset impairment losses in 2024 are expected to significantly decrease compared to the previous year.
Express News | The Pacific Securities: The change in policies for generic drug formulations presents a good opportunity for the development of the Industry.
Yifan Pharmaceutical Gets Marketing Approval for Ryzneuta Product in Brazil
Express News | Yifan Pharmaceutical: Aibegesitine α injection has been approved for market launch by the Brazilian National Health Surveillance Agency.
Yifan Pharmaceutical (002019.SZ): Ryzneuta's marketing authorization application has been approved by ANVISA.
On December 20, according to Gelonghui, Yifan Pharmaceutical (002019.SZ) announced that it recently learned through the Diário Oficial da União (the Federal Official Gazette of Brazil) that its product, Abeglistat α injection (internal research and development code: F-627, referred to as "Ryzneuta"), has received approval for marketing authorization, allowing it to be sold in Brazil.
Yifan Pharmaceutical (002019.SZ): The anti-itch ointment has received registration approval in Singapore.
On December 16, Gelonghui reported that Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary SciGen Pte. Ltd. recently received the registration approval for Chinese Patent Medicine issued by the Health Sciences Authority (HSA) of Singapore, allowing the company to exclusively market its anti-itch ointment in Singapore. The anti-itch ointment's main functions are to clear heat and eliminate dampness, dispel wind, and relieve itching. It is used as an adjunct treatment for acute and subacute eczema cases associated with damp-heat or damp obstruction.
Express News | The opening of the tenth batch of national Pharmaceutical centralized purchasing has prompted nearly 30 listed companies to announce their products are likely to be selected after the market close.
Express News | Yifan Pharmaceutical: A wholly-owned subsidiary's some products are proposed to be selected for the tenth batch of national pharmaceutical centralized procurement.
Yifan Pharmaceutical Secures Registration Approval for Neostigmine Methylsulfate Injection
Yifan Pharmaceutical (002019.SZ): Methacetin new Suxamethonium injection has obtained the pharmaceutical registration certificate.
Gelonghui, November 21 - Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Hefei Yifan Biotechnology Co., Ltd. received the 'Pharmaceutical Registration Certificate' for Methionine methylsulfonium injection issued by the National Medical Products Administration on November 21, 2024. Methionine methylsulfonium injection is an anticholinesterase drug. It is used to counteract the residual muscle relaxation effects of non-depolarizing muscle relaxants at the end of surgery, as well as for myasthenia gravis, postoperative functional intestinal distension, and urinary retention, among other conditions.
Express News | Yifan Pharmaceutical: The company's first domestically produced active pharmaceutical ingredient has been approved for sale in India.
Yifan Pharmaceutical (002019.SZ): Ginkgo leaf pill does not involve national talks.
According to Yifan Pharmaceutical (002019.SZ) on November 12th, the company stated on the investor interaction platform that the products involved in this national negotiation are Dipyridamole Oral Suspension, and Ginkgo Biloba Capsules are not part of the negotiation.